Does the media favor MDWD or IRWD?

In the previous week, MediWound had 2 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 10 mentions for MediWound and 8 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.85 beat MediWound's score of -0.26 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SVA or MDWD?

MediWound has a consensus target price of $33.00, suggesting a potential upside of 143.36%. Given MediWound's stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MediWound 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation & earnings, SVA or MDWD?

MediWound has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A MediWound $16.96M 10.27 -$23.88M -$2.26 N/A

Does the media refer more to SVA or MDWD?

In the previous week, MediWound had 8 more articles in the media than Sinovac Biotech. MarketBeat recorded 10 mentions for MediWound and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.93 beat MediWound's score of -0.26 indicating that Sinovac Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediWound 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CBIO or MDWD?

In the previous week, MediWound had 8 more articles in the media than Crescent Biopharma. MarketBeat recorded 10 mentions for MediWound and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat MediWound's score of -0.26 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediWound 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor TECX or MDWD?

In the previous week, MediWound had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 10 mentions for MediWound and 8 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.31 beat MediWound's score of -0.26 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MediWound 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend AVTE or MDWD?

MediWound has a consensus target price of $33.00, indicating a potential upside of 143.36%. Given MediWound's stronger consensus rating and higher possible upside, analysts plainly believe MediWound is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MediWound 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

MediWound (MDWD) Competitors

$13.56 +0.03 (+0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$13.58 +0.02 (+0.15%)

As of 07:34 PM Eastern

Compare

MDWD vs. IRWD, SVA, CBIO, TECX, and AVTE

Should you buy MediWound stock or one of its competitors? MediWound's main competitors and comparable companies include Ironwood Pharmaceuticals (IRWD), Sinovac Biotech (SVA), Crescent Biopharma (CBIO), Tectonic Therapeutic (TECX), and Aerovate Therapeutics (AVTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MediWound compare to Ironwood Pharmaceuticals?

MediWound (NASDAQ:MDWD) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Ironwood Pharmaceuticals has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.27	-$23.88M	-$2.26	N/A
Ironwood Pharmaceuticals	$296.15M	2.40	$24.02M	$0.77	5.60

46.8% of MediWound shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MediWound presently has a consensus target price of $33.00, suggesting a potential upside of 143.36%. Ironwood Pharmaceuticals has a consensus target price of $6.23, suggesting a potential upside of 44.62%. Given MediWound's higher possible upside, analysts clearly believe MediWound is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, MediWound had 2 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 10 mentions for MediWound and 8 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.85 beat MediWound's score of -0.26 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a net margin of 33.36% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -44.77% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-44.77%	-23.23%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

MediWound has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Summary

Ironwood Pharmaceuticals beats MediWound on 11 of the 16 factors compared between the two stocks.

How does MediWound compare to Sinovac Biotech?

Sinovac Biotech (NASDAQ:SVA) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

46.8% of MediWound shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MediWound has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
MediWound	$16.96M	10.27	-$23.88M	-$2.26	N/A

In the previous week, MediWound had 8 more articles in the media than Sinovac Biotech. MarketBeat recorded 10 mentions for MediWound and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.93 beat MediWound's score of -0.26 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sinovac Biotech has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, MediWound has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market.

Sinovac Biotech has a net margin of 0.00% compared to MediWound's net margin of -170.10%. Sinovac Biotech's return on equity of 0.00% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
MediWound	-170.10%	-44.77%	-23.23%

MediWound has a consensus target price of $33.00, suggesting a potential upside of 143.36%. Given MediWound's stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Sinovac Biotech and MediWound tied by winning 7 of the 14 factors compared between the two stocks.

How does MediWound compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Crescent Biopharma currently has a consensus price target of $29.40, suggesting a potential upside of 71.53%. MediWound has a consensus price target of $33.00, suggesting a potential upside of 143.36%. Given MediWound's higher possible upside, analysts clearly believe MediWound is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, MediWound had 8 more articles in the media than Crescent Biopharma. MarketBeat recorded 10 mentions for MediWound and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat MediWound's score of -0.26 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Crescent Biopharma has a net margin of 0.00% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -44.77% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
MediWound	-170.10%	-44.77%	-23.23%

MediWound has higher revenue and earnings than Crescent Biopharma. MediWound is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	58.73	-$153.94M	-$6.72	N/A
MediWound	$16.96M	10.27	-$23.88M	-$2.26	N/A

Crescent Biopharma has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, MediWound has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

Summary

Crescent Biopharma beats MediWound on 9 of the 16 factors compared between the two stocks.

How does MediWound compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Tectonic Therapeutic presently has a consensus target price of $77.80, suggesting a potential upside of 122.86%. MediWound has a consensus target price of $33.00, suggesting a potential upside of 143.36%. Given MediWound's higher possible upside, analysts clearly believe MediWound is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Tectonic Therapeutic has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market. Comparatively, MediWound has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

In the previous week, MediWound had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 10 mentions for MediWound and 8 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.31 beat MediWound's score of -0.26 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Tectonic Therapeutic has a net margin of 0.00% compared to MediWound's net margin of -170.10%. Tectonic Therapeutic's return on equity of -35.26% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
MediWound	-170.10%	-44.77%	-23.23%

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MediWound has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
MediWound	$16.96M	10.27	-$23.88M	-$2.26	N/A

Summary

Tectonic Therapeutic beats MediWound on 9 of the 16 factors compared between the two stocks.

How does MediWound compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Aerovate Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -44.77% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
MediWound	-170.10%	-44.77%	-23.23%

MediWound has a consensus target price of $33.00, indicating a potential upside of 143.36%. Given MediWound's stronger consensus rating and higher possible upside, analysts plainly believe MediWound is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

46.8% of MediWound shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, MediWound has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market.

In the previous week, MediWound had 10 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 10 mentions for MediWound and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat MediWound's score of -0.26 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
MediWound	Neutral

MediWound has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
MediWound	$16.96M	10.27	-$23.88M	-$2.26	N/A

Summary

MediWound beats Aerovate Therapeutics on 10 of the 15 factors compared between the two stocks.

Get MediWound News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDWD vs. The Competition

Export

Metric	MediWound	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$173.89M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-7.53	10.67	269.06	25.28
Price / Sales	10.27	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	3.99	16.78	12.91	6.24
Net Income	-$23.88M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-5.77%	1.74%	1.12%	1.07%
1 Month Performance	-4.84%	1.60%	1.79%	1.03%
1 Year Performance	-26.98%	56.43%	67.69%	20.77%

MediWound Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDWD MediWound	3.048 of 5 stars	$13.56 +0.2%	$33.00 +143.4%	-27.8%	$173.89M	$16.96M	N/A	80	News Coverage Earnings Report Analyst Forecast
IRWD Ironwood Pharmaceuticals	3.1455 of 5 stars	$4.30 +6.2%	$6.23 +45.0%	+274.3%	$660.39M	$296.15M	5.58	220
SVA Sinovac Biotech	0.9343 of 5 stars	$6.47 flat	N/A	N/A	$644.66M	$386.01M	N/A	3,008	News Coverage High Trading Volume
CBIO Crescent Biopharma	3.1329 of 5 stars	$16.69 -3.7%	$29.40 +76.2%	+19.6%	$643.70M	$10.84M	N/A	50
TECX Tectonic Therapeutic	2.984 of 5 stars	$31.87 -2.6%	$77.80 +144.1%	+53.8%	$639.46M	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDWD) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediWound (MDWD) Competitors

MDWD vs. IRWD, SVA, CBIO, TECX, and AVTE

How does MediWound compare to Ironwood Pharmaceuticals?

Summary

How does MediWound compare to Sinovac Biotech?

Summary

How does MediWound compare to Crescent Biopharma?

Summary

How does MediWound compare to Tectonic Therapeutic?

Summary

How does MediWound compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediWound (MDWD) Competitors

MDWD vs. IRWD, SVA, CBIO, TECX, and AVTE

How does MediWound compare to Ironwood Pharmaceuticals?

Which has higher valuation and earnings, MDWD or IRWD?

Do insiders and institutionals have more ownership in MDWD or IRWD?

Do analysts rate MDWD or IRWD?

Does the media favor MDWD or IRWD?

Is MDWD or IRWD more profitable?

Which has more risk and volatility, MDWD or IRWD?

Summary

How does MediWound compare to Sinovac Biotech?

Do institutionals and insiders hold more shares of SVA or MDWD?

Which has stronger valuation & earnings, SVA or MDWD?

Does the media refer more to SVA or MDWD?

Which has more risk & volatility, SVA or MDWD?

Is SVA or MDWD more profitable?

Do analysts rate SVA or MDWD?

Summary

How does MediWound compare to Crescent Biopharma?

Do analysts prefer CBIO or MDWD?

Does the media favor CBIO or MDWD?

Do insiders and institutionals have more ownership in CBIO or MDWD?

Is CBIO or MDWD more profitable?

Which has better earnings & valuation, CBIO or MDWD?

Which has more risk & volatility, CBIO or MDWD?

Summary

How does MediWound compare to Tectonic Therapeutic?

Do analysts prefer TECX or MDWD?

Which has more volatility & risk, TECX or MDWD?

Does the media favor TECX or MDWD?

Is TECX or MDWD more profitable?

Do insiders & institutionals have more ownership in TECX or MDWD?

Which has higher valuation & earnings, TECX or MDWD?

Summary

How does MediWound compare to Aerovate Therapeutics?

Is AVTE or MDWD more profitable?

Do analysts recommend AVTE or MDWD?

Do insiders and institutionals believe in AVTE or MDWD?

Which has more volatility & risk, AVTE or MDWD?

Does the media refer more to AVTE or MDWD?

Which has stronger valuation and earnings, AVTE or MDWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools